If the results are confirmed in the ongoing Phase 3 ASPEN study, we may have our first drug for treatment of bronchiectasis! #NTMTwitterJC
0:01
Latest posts 5
Skin and dental issues that were adverse events of special interest were also more common in the brensocatib groups but discontinuation was unusual, occurring in only 7% in the brensotatib arms vs 11% in the placebo. #NTMTwitterJC
It was also safe. SAEs were more common in the placebo group. Headache and dyspnea were more common with brensocatib affecting 4-10% of patients. #NTMTwitterJC
Neutrophil elastase levels were lower with both brensocatib doses compared with placebo and returned to normal within 4 weeks of stopping the drug. #NTMTwitterJC
It worked! Brensocatib reduced the time to first exacerbation compared with placebo (primary) and decreased the frequency of exacerbations including severe exacerbations (secondary). #NTMTwitterJC
